Provided by Tiger Trade Technology Pte. Ltd.

Revelation Biosciences, Inc.

1.13
0.0000
Post-market: 1.12-0.0100-0.88%19:43 EDT
Volume:34.89K
Turnover:39.50K
Market Cap:4.20M
PE:-0.05
High:1.17
Open:1.13
Low:1.11
Close:1.13
52wk High:44.77
52wk Low:1.11
Shares:3.72M
Float Shares:1.27M
Volume Ratio:0.62
T/O Rate:2.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-23.9500
EPS(LYR):-1,052.1977
ROE:-131.38%
ROA:-62.28%
PB:0.47
PE(LYR):0.00

Loading ...

Revelation Biosciences to host fireside chat at the 38th Annual Roth Conference

Reuters
·
Mar 24

Revelation Biosciences held a special shareholder meeting

Reuters
·
Mar 20

Revelation Biosciences to host fireside chat at Roth Conference

Reuters
·
Mar 19

Revelation Biosciences price target lowered to $16 from $20 at Roth Capital

TIPRANKS
·
Feb 27

Revelation Biosciences Q4 net loss widens

Reuters
·
Feb 27

Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate

Benzinga
·
Feb 27

Revelation Biosciences FY 2025 net loss narrows to USD 8.9 million

Reuters
·
Feb 27

Revelation Biosciences Raises $7.3 Million Through Unregistered Warrant Exercise

Reuters
·
Jan 29

Revelation Biosciences Inc trading halted, news pending

TIPRANKS
·
Jan 28

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

Reuters
·
Jan 28

Revelation Biosciences Announces 1-for-4 Reverse Stock Split

Reuters
·
Jan 26

Revelation Biosciences Raises $11 Million Through Immediate Warrant Exercise

Reuters
·
Jan 26

Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?

Benzinga_recent_news
·
Jan 23

Revelation reaches agreement with FDA on Gemini approval pathway

TIPRANKS
·
Jan 21

Revelation Biosciences Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment

Reuters
·
Jan 14

Revelation Biosciences Grants 90,000 RSUs to New Employee

Reuters
·
Jan 13

Revelation Biosciences Prepares Gemini for Late-Stage Acute Kidney Injury Trials

Reuters
·
Dec 04, 2025

Revelation Says On Track for FDA Meeting Later This Year

MT Newswires Live
·
Nov 21, 2025

Revelation Biosciences on track for end-of-phase 1 meeting later this year

TIPRANKS
·
Nov 20, 2025

Revelation Biosciences Advances Gemini Toward FDA Review for Acute Kidney Injury

Reuters
·
Nov 20, 2025